Das Studienregister der UME

allo-APZ2-CVU-III

A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06489028

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

Berufsordnung (BO) / Nicht-interventionell

CFT1946-1101

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of Cft1946 as Monotherapy and in Combination with Trametinib in Subjects with Braf-V600 Mutant Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

NCT-Nummer: NCT05668585

D346BC00001 LAVENDER

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Animalarial Therapy

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

EudraCT-Nummer: 2021-003698-70

NCT-Nummer: NCT06015737

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

GSK 219538

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Target Engement of GSK1070806 SC injection in participants with Moderate to Severe Atopic Dermatitis

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

IFX-1-P3.4

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum.

Arzneimittelgesetz (AMG) / Phase 3, Interventionell, Multizentrisch

NCT-Nummer: NCT05964413

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F 106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06112314

IMCgp100-203 

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-502732-39-00

NCT-Nummer: NCT05549297

M1095-HS-301 MoonLake

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa

Clinical Trial Regulation (CTR) / Interventionell

M1095-PPP-201

A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected High-Risk-Melanoma

Clinical Trial Regulation (CTR) / Interventionell

NCT-Nummer: NCT05608291

SKABUP

Multizentrische, prospektive, randomisierte, doppelblinde Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit der Therapie der Skabies mit zwei unterschiedlich konzentrierten Permethrin-Cremes

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

23-BI-1607-02

AN OPEN-LABEL, MULTICENTRE PHASE 1B/2A CLINICAL TRIAL OF BI-1607, AN FC-ENGINEERED MONOCLONAL ANTIBODY TO FCyRIIB (CD32B), IN COMBINATION WITH IPILIMUMAB AND PEMBROLIZUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch